Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling. |
|
Device | ABBOTT REALTIME HCV, ABBOTT REALTIME HCV AMPLIFICATION REAGENT KIT, ABBOTT REALTIME HVC CONTROL KIT, ABBOTT REALTIME HCV |
Generic Name | Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus |
Regulation Number | 866.3170 |
Applicant | ABBOTT MOLECULAR, INC. 1300 EAST TOUHY AVENUE DES PLAINES, IL 60018 |
PMA Number | P100017 |
Date Received | 05/18/2010 |
Decision Date | 05/17/2011 |
Reclassified Date
|
12/22/2021 |
Product Code |
MZP |
Docket Number | 11M-0349 |
Notice Date | 05/20/2011 |
Advisory Committee |
Microbiology |
Clinical Trials | NCT00202839
|
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement THE APPROVAL OF REALTIME HCV, ABBOTT REALTIME HCV AMPLIFICATION REAGENT KIT, ABBOTT REALTIME HCV CONTROL KIT, ABBOTT REALTIME HCV CALIBRATOR KIT, AND OPTIONAL UNG URACIL-N-GLYCOSYLASE (UNG) FOR USE IN CONJUNCTION WITH ABBOTT REALTIME HCV. THIS DEVICE IS INDICATED FOR: ABBOTT REALTIME HCV AMPLIFICATION REAGENT KIT, THE ABBOTT REAL TIME HCV ASSAY IS AN IN VITRO REVERSE TRANSCRIPTION- POLYMERASE CHAIN REACTION (RT-PCR) ASSAY FOR USE WITH THE ABBOTT MSAMPLE PREPARATION SYSTEM REAGENTS AND WITH THE ABBOTT M2000SP AND M2000RY4 INSTRUMENTS FOR THE QUANTITATION OF HEPATITIS C VIRAL (HCV) RNA IN HUMAN SERUM OR PLASMA (EDTA) FROM HCV-INFECTED INDIVIDUALS. SPECIMENS CONTAINING HCV GENOTYPES 1-6 HAVE BEEN VALIDATED FOR QUANTITATION IN THE ASSAY. THE ABBOTT REALTIME HCV ASSAY IS INTENDED FOR USE AS AN AID IN THE MANAGEMENT OF HCV-INFECTED PATIENTS UNDERGOING ANTIVIRAL THERAPY. THE ASSAY MEASURES HCV RNA LEVELS AT BASELINE AND DURING TREATMENT AND CAN BE UTILIZED TO PREDICT SUSTAINED AND NON- SUSTAINED VIROLOGICAL RESPONSE TO HCV THERAPY. THE RESULTS FROM THE REALTIME HCV ASSAY MUST BE INTERPRETED WITHIN THE CONTEXT OF ALL RELEVANT CLINICAL AND LABORATORY FINDINGS. ASSAY PERFORMANCE CHARACTERISTICS HAVE BEEN ESTABLISHED FOR INDIVIDUALS TREATED WITH PEGINTERFERON ALFA-2A OR 2B PLUS RIBAVIRIN. NO INFORMATION IS AVAILABLE ON THE ASSAYS PREDICTIVE VALUE WHEN OTHER THERAPIES ARE USED. ASSAY PERFORMANCE FOR DETERMINING THE STATE OF HCV INFECTION HAS NOT BEEN ESTABLISHED. THE ABBOTT REALTIME HCV ASSAY IS NOT FOR SCREENING BLOOD, PLASMA, SERUM OR TISSUE DONORS FOR HCV, OR TO BE USED AS A DIAGNOSTIC TEST TO CONFIRM THE PRESENCE OF HCV INFECTION. ABBOTT REALTIME HCV CONTROL KIT, THE ABBOTT REALTIME HCV CONTROLS ARE USED TO ESTABLISH RUN VALIDITY OF THE ABBOTT REALTIME HCV ASSAY WHEN USED FOR THE QUANTITATION OF HEPATITIS C VIRUS (HCV) RNA IN HUMAN SERUM AND PLASMA (EDTA) FROM HCV INFECTED INDIVIDUALS...FOR ADDITIONAL INFO REFER TO APPROVAL ORDER. |
Approval Order | Approval Order |
Summary | Summary of Safety and Effectiveness |
Labeling | Labeling
|
Supplements: |
S001 S002 S003 S004 S005 S006 S007 S008 S009 S010 S011 S012 S014 S015 S016 S017 S018 S019 S020 S021 S022 S023 S024
|
|
|